Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 03, 2024 12:15 ET | Source: Acticor Biotech

Acticor Biotech updates its glenzocimab clinical development plan for the treatment of cardiovascular emergencies

Acticor Biotech updates its glenzocimab clinical development plan for the treatment of cardiovascular emergencies New analyses of ACTISAVE phase 2/3 study show positive trends for...
February 07, 2024 12:00 ET | Source: Acticor Biotech

The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first clinical trial evaluating glenzocimab for heart attack

University of Birmingham and Acticor Biotech News ReleaseLimited clinical access available The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE,...
November 07, 2023 04:34 ET | Source: Acticor Biotech

Acticor Biotech a finalisé le recrutement des patients de son étude de phase 2/3 dans l’Accident Vasculaire Cérébral

Acticor Biotech a finalisé le recrutement des patients de son étude de phase 2/3 dans l’Accident Vasculaire Cérébral 438 patients souffrant d’un AVC ont été randomisés dans l’essai ACTISAVE...
November 07, 2023 04:34 ET | Source: Acticor Biotech

Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 study in stroke

Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 study in stroke 438 patients with stroke have been randomized in ACTISAVE study evaluating glenzocimab, in the...
September 14, 2023 12:15 ET | Source: Acticor Biotech

Acticor adapts its ACTISAVE clinical study to prepare the registration of glenzocimab for the treatment of stroke

ACTICOR adapts its ACTISAVE clinical study to prepare the registration of glenzocimab for the treatment of stroke Clinical results from ACTISAVE phase 2/3 study now expected in the second quarter...